BridgeBio have demonstrably advanced the development of the innovative therapy for cardiac amyloidosis, utilizing the compound. Initial trial results indicates significant outcomes for patients affected by the serious illness. This effort underscores BridgeBio's focus to addressing significant medical needs in a heart space. Attruby: BridgeBio's N